Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis

NCT07605741 | Not Yet Recruiting

• 1 other identifier: 2025PI149
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.

Conditions

Cardiac Amyloidosis

Keywords

Cardiac amyloidosis, Bone scans, CZT, SPECT-CT, Perugini

Outcome Measures

Primary Outcomes (1)

• to evaluate whether fast CZT-SPECT recordings can reproduce the diagnosis of ATTR-CA obtained using Perugini scoring on standard planar images, either by applying Perugini scoring to planar projections or by using quantitative parameters

  Comparison between Perugini score obtained on the bone scan scintigraphy performed with CZT SPECT and performed with conventional camera

  one day

Study Arms (1)

Patients referred for bone scintigraphy for suspected ATTR-CA

Patients referred for bone scintigraphy for suspected ATTR-CA underwent a fast cardiac CZT-SPECT acquisition followed by standard whole-body planar imaging three or four hours after 99mTc-HMDP injection

Other: bone scintigraphy

Interventions

bone scintigraphy OTHER

Fast CZT camera bone scintigraphy and bone scintigraphy with conventional camera (standard care)

Patients referred for bone scintigraphy for suspected ATTR-CA

Eligibility Criteria

• Age: 18 Years - 95 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retrospectively enrolled patients routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) . During this period, a rapid three-dimensional CZT-SPECT cardiac acquisition was systematically attempted in addition to conventional planar imaging, depending on camera availability, for diagnostic purposes, particularly for identifying blood-pool activity and other extracardiac confounding uptake areas

You may qualify if:

• Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.

You may not qualify if:

• Patients who object to the use of their data

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

MeSH Terms

Conditions

Amyloid Neuropathies, Familial

Condition Hierarchy (Ancestors)

Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Nervous System Diseases; Amyloid Neuropathies; Peripheral Nervous System Diseases; Neuromuscular Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Amyloidosis, Familial; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases; Amyloidosis; Proteostasis Deficiencies

Central Study Contacts

Pierre-Yves MARIE, MD,PhD

CONTACT

0383153909; py.marie@chru-nancy.fr

Véronique ROCH, MSc

CONTACT

0383154276; v.roch@chru-nancy.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prinicipal Investigator

Study Record Dates

• First Submitted: May 6, 2026
• First Posted: May 26, 2026
• Study Start: May 30, 2026
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): July 30, 2026
• Last Updated: May 26, 2026

Record last verified: 2026-05